[1] |
Kim N, Cho SG. Clinical applications of mesenchymal stem cells. Korean J Intern Med, 2013, 28: 387-402.
|
[2] |
Berardis S, Lombard C, Evraerts J, et al. Gene expression profiling and secretome analysis differentiate adult-derived human liver stem/progenitor cells and human hepatic stellate cells. PLoS One, 2014, 9: e86137.
|
[3] |
姜华, 高健鹏. 骨髓间充质干细胞治疗肝脏疾病研究进展. 实用肝脏病杂志, 2015, 18: 217-220.
|
[4] |
Fernandez Vallone VB, Romaniuk MA, Choi H, et al. Mesenchymal stem cells and their use in therapy: what has been achieved. Differentiation, 2013, 85: 1-10.
|
[5] |
Saeed H, Ahsan M, Saleem Z, et al. Mesenchymal stem cells (MSCs) as skeletal therapeutics - an update. J Biomed Sci, 2016, 23:41.
|
[6] |
Tso D, McKinnon RD. Cell replacement therapy for central nervous system diseases. Neural Regen Res, 2015, 10: 1356-1358.
|
[7] |
Somoza RA, Welter JF, Correa D, et al. Chondrogenic differentiation of mesenchymal stem cells: challenges and unfulfilled expectations. Tissue Eng Part B Rev, 2014, 20: 596-608.
|
[8] |
Al Ghrbawy NM, Afify RA, Dyaa N, et al. Differentiation of Bone Marrow: Derived Mesenchymal Stem Cells into Hepatocyte-like Cells. Indian J Hematol Blood Transfus, 2016, 32: 276-283.
|
[9] |
Khuu DN, Scheers I, Ehnert S, et al. In vitro differentiated adult human liver progenitor cells display mature hepatic metabolic functions: a potential tool for in vitro pharmacotoxicological testing. Cell Transplant, 2011, 20: 287-302.
|
[10] |
Basciano L, Nemos C, Foliguet B, et al. Long term culture of mesenchymal stem cells in hypoxia promotes a genetic program maintaining their undifferentiated and multipotent status. BMC Cell Biol, 2011, 12: 12.
|
[11] |
Ma OK, Chan KH. Immunomodulation by mesenchymal stem cells: Interplay between mesenchymal stem cells and regulatory lymphocytes. World J Stem Cells, 2016, 8: 268-278.
|
[12] |
Fan L, Hu C, Chen J, et al. Interaction between Mesenchymal Stem Cells and B-Cells. Int J Mol Sci, 2016, 17: 650.
|
[13] |
Liu WH, Song FQ, Ren LN, et al. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J Cell Mol Med, 2015, 19: 511-520.
|
[14] |
Machado Cde V, Telles PD, Nascimento IL. Immunological characteristics of mesenchymal stem cells. Rev Bras Hematol Hemoter, 2013, 35: 62-67.
|
[15] |
Bansal MB. Hepatic stellate cells: fibrogenic, regenerative or both? Heterogeneity and context are key. Hepatol Int, 2016, 10: 902-908.
|
[16] |
Zhu Y, Miao Z, Gong L, et al. Transplantation of mesenchymal stem cells expressing TIMP-1-shRNA improves hepatic fibrosis in CCl(4)-treated rats. Int J Clin Exp Pathol, 2015, 8: 8912-8920.
|
[17] |
Chen S, Xu L, Lin N, et al. Activation of Notch1 signaling by marrow-derived mesenchymal stem cells through cell-cell contact inhibits proliferation of hepatic stellate cells. Life Sci, 2011, 89: 975-981.
|
[18] |
Zhao W, Li JJ, Cao DY, et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol, 2012, 18: 1048-1058.
|
[19] |
Ahmed SK, Mohammed SA, Khalaf G, et al. Role of Bone Marrow Mesenchymal Stem Cells in the Treatment of CCL4 Induced Liver Fibrosis in Albino Rats: A Histological and Immunohistochemical Study. Int J Stem Cells, 2014, 7: 87-97.
|
[20] |
Meier RP, Mahou R, Morel P, et al. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice. J Hepatol, 2015, 62: 634-641.
|
[21] |
Truong NH, Nguyen NH, Le TV, et al. Comparison of the Treatment Efficiency of Bone Marrow-Derived Mesenchymal Stem Cell Transplantation via Tail and Portal Veins in CCl4-Induced Mouse Liver Fibrosis. Stem Cells Int, 2016, 2016:5720413.
|
[22] |
Schubert T, Xhema D, Veriter S, et al. The enhanced performance of bone allografts using osteogenic-differentiated adipose-derived mesenchymal stem cells. Biomaterials, 2011, 32: 8880-8891.
|
[23] |
陈成伟. 从真实数据中汲取经验教训才能推动干细胞在肝病领域的转化应用. 肝脏, 2016, 21: 527,535.
|
[24] |
Peng L, Xie DY, Lin BL, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology, 2011, 54: 820-828.
|
[25] |
Amin MA, Sabry D, Rashed LA, et al. Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study. Clin Transplant, 2013, 27: 607-612.
|
[26] |
El-Ansary M, Abdel-Aziz I, Mogawer S, et al. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev, 2012, 8: 972-981.
|
[27] |
Jang YO, Kim YJ, Baik SK, et al. Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int, 2014, 34: 33-41.
|
[28] |
Wang L, Li J, Liu H, et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J Gastroenterol Hepatol, 2013, 28 Suppl 1:85-92.
|
[29] |
Mohamadnejad M, Alimoghaddam K, Bagheri M, et al. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int, 2013, 33: 1490-1496.
|
[30] |
Yan XL, Jia YL, Chen L, et al. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology, 2013, 57: 2274-2286.
|